
CDC Enterprises in $18m round for biospace med
CDC Entreprises, (acting on behalf of the Strategic Investment Fund -SIF), has participated in an $18m round for biospace med alongside existing investors Edmond de Rothschild Investment Partners, Crédit Agricole Private Equity, UFG Private Equity, NBGI Ventures, and COFA Invest.
The company’s lead product, EOS ultra low dose 2D/3D X-ray imager, allows full-body imaging of patients in a weight-bearing position that will enable global assessment of balance and posture. Company currently has approximately 40 employees, and has a subsidiary in Cambridge (Massachusetts, US) as well as an office in Montreal.
This new round of financing will enable the company to accelerate the market penetration of EOS in North America and Europe, so that its ultra-low-dose 2D/3D musculoskeletal imaging modality can become a routine clinical tool.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater